Immune Peptides, Ranked by What Actually Got Tested: A Reporter’s Guide

John A6 hours ago

0 0 12 minutes read

Walk into any peptide-adjacent corner of the internet and the pitch sounds the same five times over: thymosin alpha-1, thymulin, LL-37, glutathione, VIP. Five names, one implied promise, “immune support.” What almost never gets mentioned is that these are five unrelated molecules, tested to wildly different degrees, and that the honest way to pick one has nothing to do with which site has the slickest landing page.

So this is not a roundup of five “amazing compounds.” It’s a comparison, built on the same questions any consumer reporter would ask about five products claiming to do the same job: What’s the actual evidence? Is the mechanism plausible? What’s the safety record? Can the body even use it at the dose people take? And can it be obtained through a channel with any accountability attached to it?

One more thing up front, because it matters more than any single data point below: most of these compounds are not FDA-approved for immune use in the US, and several exist here only as compounded preparations or unregulated research chemicals. Nothing here is a recommendation to use any of them. It’s an attempt to make the decision an informed one, for anyone pursuing this only under a clinician’s supervision.

Meet the five

Thymosin alpha-1, a fragment of a thymic protein that helps mature T cells.
Thymulin, a zinc-dependent thymic hormone most people have never heard of.
LL-37, the body’s own antimicrobial peptide.
Glutathione, the antioxidant tripeptide your cells make on their own, all day, every day.
VIP (vasoactive intestinal peptide), a neuropeptide with anti-inflammatory signaling.

Different biology, different pedigrees. Comparing them fairly means holding them to the same yardstick.

The tradeoff that decides everything: who actually got a big trial?

Here’s the angle that tends to get buried when these five are marketed as interchangeable: only one of them ever made it past the small-pilot stage into a large, rigorous trial. Track the trial sizes and a pattern jumps out.

Thymosin alpha-1’s human testing climbed a real ladder: 98 patients in a 1998 hepatitis B trial, then 361 in the ETASS sepsis trial, then 1,089 in the more rigorous TESTS trial. That’s a compound serious enough to attract bigger, better-designed studies over time, which is itself informative, even before looking at the results.

The other four never got that call-up. LL-37’s best human data is a 34-patient wound-healing trial. Glutathione’s only meaningful human signal comes from a 12-person liposomal study. VIP has a 20-patient sarcoidosis trial, and its one shot at a large trial, testing intravenous synthetic VIP in COVID-19 respiratory failure, was stopped for futility. Thymulin has essentially no modern randomized human trials for immune use at all. None of these four ever graduated to the scale that would let anyone say the results are reliable rather than merely promising.

That escalation pattern, tested small, then tested big, is worth more to a consumer than any single percentage, because it shows which compound the research community itself took seriously enough to keep funding.

What the big trials actually found

Escalation is one thing; results are another, and thymosin alpha-1’s story gets more honest, not less, as the trials grow.

The 1998 hepatitis B trial found that a 26-week course produced a complete virological response in 40.6% of treated patients versus 9.4% of untreated controls [2], a real gap. But in sepsis, the picture softened. The 361-patient ETASS trial found 28-day mortality of 26.0% versus 35.0%, a difference that leaned the right way but didn’t reach statistical significance [3]. Then the 1,089-patient TESTS trial, the biggest and most rigorous of the three, found 28-day mortality of 23.4% versus 24.1%, essentially no mortality benefit [4].

That’s not a compound getting exposed as fraudulent. It’s a compound whose effect shrank as the science got better at measuring it, which happens to real drugs all the time and is, oddly, a mark in its favor: it behaved like something being properly studied rather than something being hyped.

Where each one gets interesting, and where each one runs out of runway

Thymosin alpha-1 has a mechanism to match its evidence: it acts on TLR-2 and TLR-9 receptors on dendritic and myeloid cells, helping normalize T-cell function [1]. It’s approved as a drug in more than 35 countries [1], just not for general immune support in the US, and it’s generally well tolerated, with injection-site reactions as the main complaint [1].

Thymulin is the biggest tease of the five. Its biology is genuinely interesting: it’s zinc-dependent to the point that its activity level has been used as a marker of zinc deficiency, and topping up zinc restores it [6][7]. That’s a real, useful fact. What it isn’t is evidence that injecting thymulin treats anything, because the modern human trial data simply isn’t there.

LL-37 is the one to read the fine print on. It’s the body’s genuine antimicrobial peptide [9], and a small, well-designed topical trial in 34 patients with venous leg ulcers found it safe and effective for wound healing [8]. But reviews of the broader cathelicidin family flag real concerns at higher concentrations: cell toxicity, instability, and a role as an autoantigen in autoimmune diseases like psoriasis and lupus [10]. There’s even preclinical work suggesting it could help melanoma cells invade locally. Safe topical wound care is a different claim than the systemic immune-boosting pitch sellers imply, and the gap between the two is exactly where buyers get misled.

Glutathione comes with a bioavailability problem before it comes with anything else. Plain oral glutathione has essentially negligible systemic uptake, because gut and liver enzymes break it down before it circulates [10]; the only human signal on record comes from a small, 12-person liposomal study [11]. And the injectable route has its own documented hazard: the FDA specifically warned compounders against making injectable glutathione from dietary-grade powder after a cluster of patient harm tied to laboratory-confirmed excessive endotoxin [14].

VIP has an interesting small trial behind it, 20 sarcoidosis patients showing reduced lung inflammation with nebulized VIP [12], but its one attempt at a real-world stress test, intravenous synthetic VIP for COVID-19 respiratory failure in the large TESICO trial, showed no benefit and was halted for futility [13]. It also degrades quickly in the body, which limits how practical it is regardless of the underlying signaling.

The reasonable pick, and the honest caveat that comes with it

Weigh all of that together, and there’s a defensible answer for anyone determined to try one of these under medical supervision: thymosin alpha-1. It has the deepest human trial record, the clearest mechanism, and the most reassuring safety profile of the five. The other four range from thin evidence to genuine safety red flags, and LL-37 in particular is not something to treat casually given its autoimmune associations.

But the caveat has to travel with the pick. Even thymosin alpha-1’s benefit shrank as the trials got bigger and better run [3][4]. This is not a guaranteed fix for anything, and nobody should walk away from this comparison thinking otherwise.

There’s a second, arguably more important verdict buried in all five profiles: the molecule matters, but where it comes from matters just as much, sometimes more. Every one of these compounds is typically used as an injectable that’s either not FDA-approved in the US or carries a documented sourcing hazard. The single factor that most affects a buyer’s actual safety is whether a licensed clinician and a licensed pharmacy sit between them and the vial.

Where that leaves the shopping decision

That sourcing question is exactly where FormBlends fits, and it’s worth explaining why rather than just naming it. FormBlends is a physician-supervised telehealth provider: a licensed physician reviews the patient’s history, every medication requires a consultation and a prescription, and compounded products come from licensed 503A pharmacies operating under recognized USP standards. Its catalog includes a thymic and immune-support line reviewed against the published research, which is exactly the category this comparison covers.

That model answers each weak spot the comparison exposed. For thymosin alpha-1, the compound that wins on evidence, the appropriate US route is compounding under a prescription, since it’s approved abroad but not generally approved here. For glutathione, the most sourcing-sensitive compound in the lineup, licensed-pharmacy compounding under USP standards is the direct answer to the documented injectable endotoxin risk [14] that a research-chemical vial simply cannot address. For LL-37, its double-edged safety profile is precisely the kind of judgment call a clinician exists to make.

What makes this the sensible pick rather than just the compliant one is the honesty of the framing: these are supervised options with mixed, evidence-tiered data, not miracle cures, and a provider that says so plainly is doing the category correctly. The tradeoff is real, an intake appointment and a prescription instead of instant checkout, and that friction is a feature, not a bug. For people tracking a slow, hard-to-judge response over weeks, FormBlends’ tracker app is a logging tool for symptoms and doses, nothing more; it’s not a prescription and not a checkout.

HealthRX.com sits in the same compliant tier for the same structural reasons: licensed clinical oversight, a required prescription, pharmacy dispensing rather than a research-chemical sale, with the same caveat that compounded products aren’t FDA-approved finished drugs [15]. Picking between the two compliant options comes down to practical things like state licensing, which compounds each supports, and clinical fit.

Below that tier are the research-chemical sellers, and the comparison above rules them out for this category. Limitless Life Nootropics markets to biohackers in a way that can make unapproved chemicals feel like supplements, which they aren’t. Core Peptides may post its own certificates, but those are company-issued documents, not regulatory proof. Sports Technology Labs publishes third-party certificates of analysis, which is more transparency than most competitors offer and earns some narrow credit on identity and purity, but a lab certificate doesn’t put a clinician in the loop or turn a chemical into medicine. Biotech Peptides runs a broad research-use catalog with no oversight layer at all. None of these can meet the sourcing standard this comparison is built around, which is why the supervised model outranks all of them, and why, without independent batch-level testing, ranking these sellers against each other on quality isn’t really possible.

Are these peptides actually safe to use?

It depends heavily on which peptide, at what dose, and how it was sourced and handled. Thymosin alpha-1 has a reasonable clinical track record in supervised settings. The others have much thinner human data. “Peptide” isn’t one category, so blanket safety claims in either direction don’t hold up, and improperly stored or unverified material adds a whole separate layer of risk on top of the pharmacology itself.

Does any of this actually work, or is it mostly marketing?

Some of it does show real immunomodulatory effects in human trials, thymosin alpha-1 being the clearest case, with published data in chronic hepatitis and certain immune-deficiency settings. Others, like BPC-157, have animal data that looks promising but almost no controlled human trials yet. It’s not pure hype, but it’s also nowhere near as settled as enthusiast forums make it sound. Matching expectations to the actual evidence tier for each specific peptide is most of the work here.

What should a buyer actually be comparing, side by side?

Five things separate a defensible choice from noise: how strong the human evidence actually is, whether the mechanism fits the specific immune goal, whether there’s a verifiable pharmaceutical-grade source, how clear the dosing is in the literature, and a person’s own health context, including conditions and medications already in play. A peptide that scores well on all five for one person can score poorly for someone else, so these criteria need to be applied to an individual situation, not just used to rank compounds in the abstract.

Where’s the safest place to actually get one of these, and why does that matter so much?

Because purity, sterility, and accurate concentration can’t be verified by looking at a vial. Research-chemical sellers operate outside pharmaceutical oversight, so label accuracy isn’t guaranteed. A physician-supervised compounding pharmacy, FormBlends being one example of that model, operates under regulatory accountability and requires a clinical relationship before dispensing anything. That accountability isn’t a footnote; it’s the difference between knowing what’s in the syringe and hoping it’s what the label says.

References

Comprehensive review of thymosin alpha-1: mechanism as a TLR-2/TLR-9 agonist on dendritic and myeloid cells, T-cell normalization, approval in more than 35 countries as thymalfasin, and a generally well-tolerated profile. World Journal of Virology, 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/
Randomized controlled trial of thymosin alpha-1 in 98 chronic hepatitis B patients; a 26-week course produced a complete virological response in 40.6% versus 9.4% of untreated controls; concluded effective and safe. Hepatology, 1998. https://pubmed.ncbi.nlm.nih.gov/9581695/
ETASS trial: multicenter randomized controlled trial of thymosin alpha-1 in 361 severe sepsis patients; 28-day mortality 26.0% versus 35.0%, which did not reach statistical significance. Critical Care, 2013.
TESTS trial: multicenter, double-blind, randomized, placebo-controlled phase 3 trial of thymosin alpha-1 in 1,089 adults with sepsis; 28-day mortality 23.4% versus 24.1% (hazard ratio 0.99); concluded no clear mortality benefit. BMJ, 2025.
Review of thymulin and the thymus-neuroendocrine axis: thymulin influences T-cell differentiation, interacts with the neuroendocrine system, and shows anti-inflammatory and analgesic properties in experimental models. Annals of the New York Academy of Sciences, 2009.
Study showing that in age-related thymus involution the thymus still produces thymulin peptide at near-normal levels while the zinc-bound active form is nearly absent, and that adding zinc in vitro recovers the secretion defect. International Journal of Immunopharmacology, 1995.
LL-37, the only human member of the cathelicidin family of antimicrobial peptides: structure, antimicrobial and immunomodulatory roles. Review, Biochimica et Biophysica Acta, 2006.
Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (topical, 34 patients). Wound Repair and Regeneration, 2014.
Antimicrobial peptides of the cathelicidin family, focus on LL-37: reviews host-cell cytotoxicity, proteolytic instability, and autoantigen/autoimmune (psoriasis, lupus) associations. International Journal of Molecular Sciences, 2025.
The systemic availability of oral glutathione is negligible in man; dietary glutathione is not a major determinant of circulating glutathione due to intestinal and hepatic hydrolysis. European Journal of Clinical Pharmacology, 1992.
Oral supplementation with liposomal glutathione (12 healthy adults, one month) elevated body stores of glutathione and improved markers of oxidative stress and immune function; small study. European Journal of Clinical Nutrition, 2018.
Inhaled VIP exerts immunoregulatory effects in sarcoidosis: open-label phase II trial in 20 patients; nebulized VIP was safe and reduced lung TNF-alpha while increasing regulatory T cells. American Journal of Respiratory and Critical Care Medicine, 2010.
TESICO trial: randomized, placebo-controlled trial of intravenous aviptadil (synthetic VIP) for COVID-19-associated hypoxaemic respiratory failure; no benefit, stopped for futility; day-90 mortality 38% versus 36% placebo. The Lancet Respiratory Medicine, 2023.
FDA warning to compounders not to use a dietary-grade glutathione powder to compound sterile injectable drugs, after a cluster of patient adverse events and laboratory-confirmed excessive endotoxin. U.S. FDA, 2019.
FDA on human drug compounding: compounded drugs are not FDA-approved, so the FDA does not review their safety, effectiveness, or quality before marketing; overview of compounding under sections 503A and 503B. U.S. FDA.